Effects of Renin-Angiotensin Blockade on Sympathetic Reactivity and β- Adrenergic Pathway in the Spontaneously Hypertensive Rat

Hypertension

Volumn 30, Issue 2, 1997, Pages 278-287

  K Laflamme, Annik ^b   Oster, Laurence ^b   Cardinal, René ^b   De Champlain, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Adenylyl cyclase; Adrenergic; Autonomic nervous system; Beta; Enalaprilat; Genetic; Hypertension; Losartan; Receptors; Renin angiotensin system

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; ENALAPRILAT; LOSARTAN; NITROPRUSSIDE SODIUM;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPATHETIC TONE;

EID: 0030818680     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.30.2.278     Document Type: Article

References (45)

1. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 1993;43:1-20.
2. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation. 1988;77(suppl I):I-4-I-13.
3. Keuneke C, Yacullo R, Metzger R, Hellmann T, Peters J, Ganten D. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition. Eur Heart J. 1990; 11(suppl D):11-16.
4. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol. 1992; 19(suppl 6):S80-S86.
5. Story DF, Ziogas J. Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci. 1987;8:269-271.
6. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension. J Hypertens. 1994;12:1333-1338.
7. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 1977;21:625-636.
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193: 265-275.
9. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci. 1949;51:660-672.
10. DeLéan A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol. 1978; 235:E97-E102.
11. Salomon Y. Adenylate cyclase assay. In: Brooker G, Greengard P, Robison GA, eds. Advances in Cyclic Nucleotide Research. New York, NY: Raven Press Publishers; 1979;10:35-55.
12. Furtek CI, Lo M-W. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1992;573:295-301.
13. Moreau P, Oster L, Laflamme AK, Lambert C, de Champlain J. Relationship between the plasma and the efficacy of losartan during a chronic therapy in the rat. Can J Physiol Pharmacol. 1994;72(suppl 1):178. Abstract.
14. Oster L, Laflamme AK, Moreau P, de Champlain J. Effect of losartan and enalaprilat in inositol phosphate accumulation in aorta of SHR. J Hypertens. 1994;12(suppl 3):S88. Abstract.
15. Mizuno K, Niimura S, Tani M, Haga H, Gomibuchi T, Sanada H, Fukuchi S. Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats. Eur J Pharmacol. 1992;215:305-308.
16. Mizuno K, Tani M, Hashimoto S, Niimura S, Sanada H, Watanabe H, Ohtsuki M, Fukuchi S. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci. 1992;51:367-374.
17. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Nakamura F, Ogihara T. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 1991;9:595-599.
18. Li C, Prakash O, Re RN. Altered expression of angiotensinogen gene expression in the left ventricles of the hypertensive rats. Circulation. 1989;80(suppl II):II-450. Abstract.
19. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces the regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11:1325-1350.
20. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor. Am J Hypertens. 1992;5:276-280.
21. Van Gilst WH, Scholtens E, De Graeff PA, De Langen CDJ, Wesseling H. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation. 1988; 77(suppl I):I-24-I-29.
22. Rosolowsky LJ, Campbell WB. Bradykinin stimulates aldosterone release from cultured bovine adrenocortical cells through bradykinin B2 receptors. Endocrinology. 1992;130:2067-2075.
23. Chauvin B, Richer C, Giudicelli JF. Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats. Br J Pharmacol. 1995;116:2229-2236.
24. Borkowski KR. Effect of adrenal demedullation and adrenaline on hypertension development and vascular reactivity in young spontaneously hypertensive rats. J Auton Pharmacol. 1991;11:1-14.
25. 3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously rats. Am J Hypertens. 1996;9:61-69.
26. Liard JF. The baroreceptor reflexes in experimental hypertension. Clin Exp Hypertens. 1980;2:479-498.
27. Guo GB, Abboud FM. Angiotensin II attenuates baroreceptor control of heart rate and sympathetic activity. Am J Physiol. 1984; 246:H80-H89.
28. Unger T, Badoer E, Ganten D, Lang R, Rettig R. Brain angiotensin: pathways and pharmacology. Circulation. 1988;77(suppl I): I-40-I-54.
29. Bartholomeusz B, Widdop RE. Effect of acute and chronic treatment with the angiotensin II subtype 1 receptor antagonist EXP3174 on baroreflex function in conscious spontaneously hypertensive rats. J Hypertens. 1995;13:219-225.
30. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-242.
31. 2-adrenoceptor density in heart, lung and kidney of spontaneously hypertensive rats. J Auton Pharmacol 1987;7:41-51.
32. Yamada S, Ishima T, Tomita T, Hayashi M, Okada T, Hayashi E. Alterations in cardiac alpha and beta adrenoceptors during the development of spontaneous hypertension. J Pharmacol Exp Ther 1984;228:454-460.
33. Nguyen CT, de Champlain J, Bouvier M. Tissue specific changes in β-adrenergic receptors subtypes in DOCA-salt hypertensive rats. Biomed J. 1995;2:34-42.
34. Borkowski KR, Quinn P. Adrenaline and the development of spontaneous hypertension in rats. J Auton Pharmacol. 1985;5:89-100.
35. 2-adrenergic receptor. Science. 1994;264:582-586.
36. de Champlain J, Yacine A, Leblanc R, Bouvier M, Lebeau R, Nadeau R. Effects of trandolapril on the sympathetic tone and reactivity in systemic hypertension. Am J Cardiol. 1994;73:18C-25C.
37. Horn E, Corwin SJ, Steinberg SF, Chow YK, Neuberg GW, Cannon PJ, Powers ER, Bilezikian JP. Reduced lymphocyte stim ulatory guanine nucleotide regulatory protein and β-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy. Circulation. 1988;78: 1373-1379.
38. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Effect of lisinopril on cardiac adrenergic drive and myocardial β-receptor density in heart failure. Circulation. 1988; 78(suppl II):II-576. Abstract.
39. Maisel AS, Phillips C, Michel MC, Ziegler MG, Carter SM. Regulation of cardiac β-adrenergic receptors by captopril: implications for congestive heart failure. Circulation. 1989;80:669-675.
40. Hamet P, Orlov SN, Tremblay J. Intracellular signaling mechanisms in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York, NY: Raven Press Publishers; 1995:575-607.
41. McLellan AR, Milligan G, Houslay MD, Connell JMC. G-proteins in experimental hypertension: a study of spontaneously hypertensive rat myocardial and renal cortical plasma membranes. J Hypertens. 1993;11:365-372.
42. Anand-Srivastava MB. Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Biochem J. 1992;288:79-85.
43. Michel MC, Brodde O-E, Insel PA. Are cardiac G-proteins altered in rat models of hypertension? J Hypertens. 1993;11:355-363.
44. Clark CJ, Milligan G, McLellan AR, Connell JMC. Guanine nucleotide regulatory proteins in the spontaneously hypertensive rat. Hypertension. 1993;21:204-209.
45. Coquil JF, Brunelle G. Adenylate cyclase of platelets from spontaneously hypertensive rats: reduction of the inhibition by GTP. Biochem Biophys Res Commun. 1989;162:1265-1271.